<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561431</url>
  </required_header>
  <id_info>
    <org_study_id>X030108004</org_study_id>
    <nct_id>NCT00561431</nct_id>
  </id_info>
  <brief_title>High Dose CVVHDF Compared to Standard Dose CVVHDF</brief_title>
  <acronym>CVVHDF</acronym>
  <official_title>A Randomized Prospective Study Comparing High Dose Continuous Venovenous Hemodiafiltration (CVVHDF) to Standard Dose CVVHDF in Critically Ill Patients With Acute Renal Failure at the University of Alabama at Birmingham</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU
      has remained unchanged at greater than 50%, despite improvements in dialysis technology.

      The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration
      (CVVHDF) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater
      reduction in all-cause ICU mortality compared to standard CVVHDF using an ultrafiltration
      rate of 20 ml/hr/kg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the worldwide standard for renal replacement therapy is intermittent
      hemodialysis(IHD), continuous renal replacement therapy (CRRT) has emerged as an alternative
      form of renal replacement therapy in the critical care setting due to its advantages of slow
      continuous fluid removal, steady acid-base correction, and hemodynamic stability.

      There are no standard protocols for initiating or administering CRRT, and practice patterns
      vary widely among institutions, with less than 25% of patients with ARF in the ICU receiving
      this therapy in the United States.

      Various CRRT modalities are available that use diffusion, convection, or a combination of
      both to obtain adequate solute clearance. However, there is no consensus as to the optimal
      dialysis modality, adequate dialysis dose, or optimal clearance modality (convection vs.
      diffusion). Clinical trials are needed to determine the optimal method of administering CRRT,
      with respect to modality, dose of dialysis, and time of initiation of therapy.

      Although some studies suggest that a higher dose of dialysis improves survival, there have
      been no prospective randomized studies comparing the effectiveness of diffusion and
      convection, combined together, for solute clearance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The primary objective is to determine whether Continuous Venovenous Hemodiafiltration (CVVHDF) using an effluent rate of 35 ml/hr/kg (high dose) leads to an increased participant survival time as compared to CVVHDF using the standard effluent rate of 25 ml/hr/kg as measured by days on continuous renal replacement therapy (CRRT) at enrollment up to 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of Renal Function, Defined as Not Requiring Dialysis After Discontinuation of CRRT</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The number of participants who recover renal function at 30 days after enrollment in each arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard dose of dialysis</intervention_name>
    <description>Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High dose of dialysis</intervention_name>
    <description>Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; or equal to 19 yrs of age

          -  ARF defined by at least one of the following:

               -  Volume overload from inadequate urine output despite diuretic agents.

               -  Oliguria (urine output &lt; 200 ml/12hrs) despite fluid resuscitation and diuretic
                  administration.

               -  Anuria (urine output &lt; 50 ml/12 hrs).

               -  Acute azotemia (BUN &gt; or equal to 80 mg/dl).

               -  Acute hyperkalemia not responsive to medication (K+ &gt; or equal to 6.5mmol/L)

               -  An increase in serum creatinine of &gt; 2.5 mg/dl from normal values or a sustained
                  rise in serum creatinine of &gt; or equal to 1 mg/dl over baseline.

        Exclusion Criteria

          -  Patients with end stage renal disease

          -  Patients who have had more than one previous dialysis session for acute or chronic
             renal failure during the current hospitalization

          -  Patient weight greater than 125 kg

          -  Patient weight less than 50 kg

          -  Pregnancy

          -  Prisoner

          -  Non-candidacy for continuous renal replacement therapy (CRRT)

          -  Patient/surrogate refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashita J. Tolwani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham, Division of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <results_first_submitted>November 11, 2009</results_first_submitted>
  <results_first_submitted_qc>February 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2010</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Ashita Tolwani</investigator_full_name>
    <investigator_title>Principal Investigatorl</investigator_title>
  </responsible_party>
  <keyword>CVVHDF Dose Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
        </group>
        <group group_id="P2">
          <title>High Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
        </group>
        <group group_id="B2">
          <title>High Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="15"/>
                    <measurement group_id="B2" value="58" spread="16"/>
                    <measurement group_id="B3" value="60" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
        <description>The primary objective is to determine whether Continuous Venovenous Hemodiafiltration (CVVHDF) using an effluent rate of 35 ml/hr/kg (high dose) leads to an increased participant survival time as compared to CVVHDF using the standard effluent rate of 25 ml/hr/kg as measured by days on continuous renal replacement therapy (CRRT) at enrollment up to 30 days.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
            <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>High Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
            <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>The primary objective is to determine whether Continuous Venovenous Hemodiafiltration (CVVHDF) using an effluent rate of 35 ml/hr/kg (high dose) leads to an increased participant survival time as compared to CVVHDF using the standard effluent rate of 25 ml/hr/kg as measured by days on continuous renal replacement therapy (CRRT) at enrollment up to 30 days.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recovery of Renal Function, Defined as Not Requiring Dialysis After Discontinuation of CRRT</title>
        <description>The number of participants who recover renal function at 30 days after enrollment in each arm.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
            <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>High Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
            <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery of Renal Function, Defined as Not Requiring Dialysis After Discontinuation of CRRT</title>
          <description>The number of participants who recover renal function at 30 days after enrollment in each arm.</description>
          <population>intention to treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time on continuous venovenous hemodiafiltration up to 30 days.</time_frame>
      <desc>The adverse events of death and non renal recovery were not related to the intervention or unexpected. The therapy did not affect this outcome.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr</description>
        </group>
        <group group_id="E2">
          <title>High Dose Continuous Venovenous Hemodiafiltration (CVVHDF)</title>
          <description>High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="100"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="100"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ashita Tolwani, M.D.</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>2059752021</phone>
      <email>atolwani@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

